RYTM News and Press, Rhythm Pharmaceuticals Inc. From 03/01/22

The following slide deck was published by Rhythm Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Rhythm Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation

Rhythm Pharmaceuticals press release (NASDAQ:RYTM): Q4 GAAP EPS of -$0.85 beats by $0.06. Revenue of $1.82M beats by $0.12M. For further details see: Rhythm Pharmaceuticals GAAP EPS of -$0.85 beats by $0.06, revenue of $1.82M beats by $0.12M

-- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial sales of IMCIVREE in Germany and France expected in 2Q2022 – -- Enrollment completed in Phase 2 trial evaluating setm...

Rhythm Pharmaceuticals (NASDAQ:RYTM) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open. The consensus EPS Estimate is -$0.93 and the consensus Revenue Estimate is $1.7M For further details see: Rhythm Pharmaceuticals Q4 2021 Earnings Preview

NEW YORK, NY / ACCESSWIRE / February 25, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rhythm Pharmaceuticals, Inc. ("Rhythm" or the "Company") (NASDAQ:RYTM). Investors who purchased Rhythm securities are encouraged to obtain add...

Gainers: Lantheus (NASDAQ:LNTH) +34%. Evolent Health (NYSE:EVH) +18%. Clover Health (NASDAQ:CLOV) +10%. Liquidia (NASDAQ:LQDA) +10%. iRhythm Technologies (NASDAQ:IRTC) +8%. Losers: Orphazyme (NASDAQ:ORPH) -36%. Rhythm Pharmaceuticals (NASDAQ:RYTM) -24%. Tabu...

Rhythm Pharmaceuticals (NASDAQ:RYTM) is trading ~8% lower in the pre-market Thursday after the commercial-stage biopharma company announced that the U.S. Food and Drug Administration (FDA) had extended its supplemental New Drug Application (sNDA) for Imcivree. The company has sought...

-- FDA sets updated PDUFA goal date of June 16, 2022 -- -- Company also announces withdrawal of proposed Alström syndrome indication from Type II variation application under review by the EMA -- BOSTON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (N...

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced the promotions of Joe Shulman to Chief Technical Off...

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast...